Rosiglitazone and myocardial infarction: Cause for concern or misleading meta-analysis?

Diabetic Medicine

Volumn 24, Issue 9, 2007, Pages 931-933

  Bilous, R W ^a  

^a JAMES COOK UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; GLITAZONE DERIVATIVE; HEMOGLOBIN A1C; METFORMIN; ROSIGLITAZONE; SULFONYLUREA;

ANEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETES MELLITUS; DRUG COST; EDITORIAL; FLUID RETENTION; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART INFARCTION; HOSPITAL ADMISSION; HUMAN; ISCHEMIC HEART DISEASE; POSTMARKETING SURVEILLANCE; SIDE EFFECT; WEIGHT GAIN;

DIAGNOSIS, DIFFERENTIAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THIAZOLIDINEDIONES;

EID: 34548139012     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2007.02259.x     Document Type: Editorial

References (21)

1. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007 356:2457 2471.
2. Psaty BM, Furberg CD. Rosiglitazone and cardiovascular risk. N Engl J Med 2007 356:3522 3524.
3. Drazen JM, Morrissey S, Curfman GD. Rosiglitazone - continued uncertainty about safety. N Engl J Med 2007 357:63 64.
4. Nathan DM. Rosiglitazone and cardio-toxicity - weighing the evidence. N Engl J Med 2007 357:64 66.
5. Psaty BM, Furberg CD. The record on rosiglitazone and the risk of myocardial infarction. N Engl J Med 2007 357:67 69.
6. Kazi D. Rosiglitazone and implications for pharmacovigilence. Br Med J 2007 334:1233 1234.
7. Fuster V, Farkouh ME. Faster publication isn't always better. Nat Clin Pract Cardiovasc Med 2007 4:345.
8. Rosiglitazone: seeking a balanced perspective. Lancet 2007 369:1834.
9. Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Jones NP et al. Rosiglitazone evaluated for cardiovascular outcomes - an interim analysis. N Engl J Med 2007 357:28 38.
10. The DREAM Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance where impaired fasting glucose: a randomised control trial. Lancet 2006 368:1096 1105.
11. Khan SE, Haffner SM, Heise NA, Herman WH, Holman RR, James MP et al. Glycaemic durability of rosiglitazone, metformin or glyburide monotherapy. N Engl J Med 2006 355:2427 2443.
12. GlaxoSmithKline. Avandia Cardiovascular Event Modelling Project. Study number ZM2005/00181/01. Available at http://ctr.gsk.co.uk/Summary/Rosiglitazone/ III_CVmodeling.pdf Last accessed 14 June 2007.
13. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study. PROspective piAglitazone Clinical Trial In macroVascular Events: a randomised control trial. Lancet 2005 366:1279 1289.
14. The Diabetes Control Complications Trial/Epidemiology of Diabetes Interventions Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005 353:2643 2653.
15. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998 352:837 853.
16. Nathan DM. Finding new treatments for diabetes - how many, how fast. how good? N Engl J Med 2007 356:437 440.
17. Chaturvedi N, Bilous R, Hardy R, Remuzzi G, Ruggenenti P, Viberti GC. Misleading meta-analysis: a need to look beyond the headlines. Diabet Med 2007 24:587 591.
18. Roper NA, Bilous RW, Kelly WF, Unwin NC, Connolly VM. Excess mortality in a population with diabetes and the impact of material deprivation: longitudinal, population based study. Br Med J 2001 322:1389 1393.
19. The Information Centre. Report on Prescribing for Diabetes in Primary and Secondary Care in England 2007. London:NHS Publications 2007.
20. NICE. Management of Type 2 Diabetes. Management of Blood Glucose. Inherited clinical guideline G. London:National Institute for Clinical Excellence, 2002. Available at http://www.nice.org.uk Last accessed 12 July 2007.
21. Nathan DM, Holman RR, Buse JB, Sherwin R, Davidson MB, Zinman B et al. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2006 29:1963 1972.